Although numerous human STING agonists have been developed and entered clinical trials, the efficacy of STING agonist monotherapy is poor, highlighting the need to conduct more in-depth research on the mechanism of the cGAS-STING pathway in the tumor environment. The gene discussed is STING1; the disease is neoplasm.